Diaminopyridine-based potent and selective Mps1 kinase inhibitors binding to an unusual flipped-peptide conformation

ACS Medicinal Chemistry Letters

Volumn 3, Issue 7, 2012, Pages 560-564

  Kusakabe, Ken Ichi ^a   Ide, Nobuyuki ^a   Daigo, Yataro ^b,c   Itoh, Takeshi ^a   Higashino, Kenichi ^a   Okano, Yousuke ^a   Tadano, Genta ^a   Tachibana, Yuki ^a   Sato, Yuji ^a   Inoue, Makiko ^a   Wada, Tooru ^a   Iguchi, Motofumi ^a   Kanazawa, Takayuki ^a   Ishioka, Yukichi ^a   Dohi, Keiji ^a   Tagashira, Sachie ^a   Kido, Yasuto ^a   Sakamoto, Shingo ^a   Yasuo, Kazuya ^a   Maeda, Masahiro ^a   Yamamoto, Takahiko ^a   Higaki, Masayo ^a   Endoh, Takeshi ^a   Ueda, Kazuo ^a   Shiota, Takeshi ^a   Murai, Hitoshi ^a   Nakamura, Yusuke ^b   more..

^a SHIONOGI AND CO LTD   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

cancer; diaminopyridine; inhibitor; monopolar spindle 1; Mps 1; peptide flip; TTK

Indexed keywords

ANILINE; ANTINEOPLASTIC AGENT; CARBONYL DERIVATIVE; CYSTEINE; DIAMINOPYRIDINE DERIVATIVE; MONOPOLAR SPINDLE KINASE 1; PROTEIN KINASE; PYRIDINE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG ACTIVITY; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; TUMOR XENOGRAFT; X RAY ANALYSIS;

EID: 84863848852     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml3000879     Document Type: Article

References (25)

1. Fisk, H. A.; Mattison, C. P.; Winey, M. Human Mps1 protein kinase is required for centrosome duplication and normal mitotic progression Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 14875-14880
2. Stucke, V. M.; Sillje, H. H. W.; Arnaud, L.; Nigg, E. A. Human Mps1 kinase is required for the spindle assembly checkpoint but not for centrosome duplication EMBO J. 2002, 21, 1723-1732
3. Jelluma, N.; Brenkman, A. B.; van den Broek, N. J. F.; Cruijsen, C. W. A.; van Osch, M. H. J.; Lens, S. M. A.; Medema, R. H.; Kops, Geert, J. P. L. Mps1 phosphorylates borealin to control aurora B activity and chromosome alignment Cell (Cambridge, MA, U. S.) 2008, 132, 233-246
4. Saito-Hisaminato, A.; Katagiri, T.; Kakiuchi, S.; Nakamura, T.; Tsunoda, T.; Nakamura, Y. Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray DNA Res. 2002, 9, 35-45
5. Kikuchi, T.; Daigo, Y.; Katagiri, T.; Tsunoda, T.; Okada, K.; Kakiuchi, S.; Zembutsu, H.; Furukawa, Y.; Kawamura, M.; Kobayashi, K.; Imai, K.; Nakamura, Y. Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs Oncogene 2003, 22, 2192-2205
6. Yamabuki, T.; Daigo, Y.; Kato, T.; Hayama, S.; Tsunoda, T.; Miyamoto, M.; Ito, T.; Fujita, M.; Hosokawa, M.; Kondo, S.; Nakamura, Y. Genome-wide gene expression profile analysis of esophageal squamous cell carcinomas Int. J. Oncol. 2006, 28, 1375-1384
7. Daniel, J.; Coulter, J.; Woo, J.-H.; Wilsbach, K.; Gabrielson, E. High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 5384-5389
8. Colombo, R.; Caldarelli, M.; Mennecozzi, M.; Giorgini, M. L.; Sola, F.; Cappella, P.; Perrera, C.; Depaolini, S. R.; Rusconi, L.; Cucchi, U.; Avanzi, N.; Bertrand, J. A.; Bossi, R. T.; Pesenti, E.; Galvani, A.; Isacchi, A.; Colotta, F.; Donati, D.; Moll, J. Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase Cancer Res. 2010, 70, 10255-10264
9. Caldarelli, M.; Angiolini, M.; Disingrini, T.; Donati, D.; Guanci, M.; Nuvoloni, S.; Posteri, H.; Quartieri, F.; Silvagni, M.; Colombo, R. Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 4507-4511
10. Tardif, K. D.; Rogers, A.; Cassiano, J.; Roth, B. L.; Cimbora, D. M.; McKinnon, R.; Peterson, A.; Douce, T. B.; Robinson, R.; Dorweiler, I.; Davis, T.; Hess, M. A.; Ostanin, K.; Papac, D. I.; Baichwal, V.; McAlexander, I.; Willardsen, J. A.; Saunders, M.; Christophe, H.; Kumar, D. V.; Wettstein, D. A.; Carlson, R. O.; Williams, B. L. Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1 Mol. Cancer Ther. 2011, 10, 2267-2275
11. Bamborough, P.; Drewry, D.; Harper, G.; Smith, G. K.; Schneider, K. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery J. Med. Chem. 2008, 51, 7898-7914
12. Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the "gatekeeper door": Exploiting the active kinase conformation J. Med. Chem. 2010, 53, 2681-2694
13. Chu, M. L. H.; Chavas, L. M. G.; Douglas, K. T.; Eyers, P. A.; Tabernero, L. Crystal structure of the catalytic domain of the mitotic checkpoint kinase Mps1 in complex with SP600125 J. Biol. Chem. 2008, 283, 21495-21500
14. Fabian, M. A.; Biggs, W. H.; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J.-M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 2005, 23, 329-336
15. Schmidt, M.; Budirahardja, Y.; Klompmaker, R.; Medema, R. H. Ablation of the spindle assembly checkpoint by a compound targeting Mps1 EMBO Rep. 2005, 6, 866-872
16. Szczepankiewicz, B. G.; Kosogof, C.; Nelson, L. T. J.; Liu, G.; Liu, B.; Zhao, H.; Serby, M. D.; Xin, Z.; Liu, M.; Gum, R. J.; Haasch, D. L.; Wang, S.; Clampit, J. E.; Johnson, E. F.; Lubben, T. H.; Stashko, M. A.; Olejniczak, E. T.; Sun, C.; Dorwin, S. A.; Haskins, K.; Abad-Zapatero, C.; Fry, E. H.; Hutchins, C. W.; Sham, H. L.; Rondinone, C. M.; Trevillyan, J. M. Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity J. Med. Chem. 2006, 49, 3563-3580
17. Zhao, H.; Serby, M. D.; Xin, Z.; Szczepankiewicz, B. G.; Liu, M.; Kosogof, C.; Liu, B.; Nelson, L. T. J.; Johnson, E. F.; Wang, S.; Pederson, T.; Gum, R. J.; Clampit, J. E.; Haasch, D. L.; Abad-Zapatero, C.; Fry, Elizabeth, H.; Rondinone, C.; Trevillyan, J. M.; Sham, H. L.; Liu, G. Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors J. Med. Chem. 2006, 49, 4455-4458
18. Fitzgerald, C. E.; Patel, S. B.; Becker, J. W.; Cameron, P. M.; Zaller, D.; Pikounis, V. B.; O'Keefe, S. J.; Scapin, G. Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity Nat. Struct. Biol. 2003, 10, 764-769
19. Stelmach, J. E.; Liu, L.; Patel, S. B.; Pivnichny, J. V.; Scapin, G.; Singh, S.; Hop, C. E. C. A.; Wang, Z.; Strauss, J. R.; Cameron, P. M.; Nichols, E. A.; O'Keefe, S. J.; O'Neill, E. A.; Schmatz, D. M.; Schwartz, C. D.; Thompson, C. M.; Zaller, D. M.; Doherty, J. B. Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase Bioorg. Med. Chem. Lett. 2003, 13, 277-280
20. Herberich, B.; Cao, G.-Q.; Chakrabarti, P. P.; Falsey, J. R.; Pettus, L.; Rzasa, R. M.; Reed, A. B.; Reichelt, A.; Sham, K.; Thaman, M.; Wurz, R. P.; Xu, S.; Zhang, D.; Hsieh, F.; Lee, M. R.; Syed, R.; Li, V.; Grosfeld, D.; Plant, M. H.; Henkle, B.; Sherman, L.; Middleton, S.; Wong, L. M.; Tasker, A. S. Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold J. Med. Chem. 2008, 51, 6271-6279
21. Pettus, L. H.; Xu, S.; Cao, G.-Q.; Chakrabarti, P. P.; Rzasa, R. M.; Sham, K.; Wurz, R. P.; Zhang, D.; Middleton, S.; Henkle, B.; Plant, M. H.; Saris, C. J. M.; Sherman, L.; Wong, L. M.; Powers, D. A.; Tudor, Y.; Yu, V.; Lee, M. R.; Syed, R.; Hsieh, F.; Tasker, A. S. 3-Amino-7- phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38α. mitogen-activated protein kinase J. Med. Chem. 2008, 51, 6280-6292
22. Wu, B.; Wang, H.-L.; Pettus, L.; Wurz, R. P.; Doherty, E. M.; Henkle, B.; McBride, H. J.; Saris, C. J. M.; Wong, L. M.; Plant, M. H.; Sherman, L.; Lee, M. R.; Hsieh, F.; Tasker, A. S. Discovery of pyridazinopyridinones as potent and selective p38 mitogen-activated protein kinase inhibitors J. Med. Chem. 2010, 53, 6398-6411
23. Xing, L.; Shieh, H. S.; Selness, S. R.; Devraj, R. V.; Walker, J. K.; Devadas, B.; Hope, H. R.; Compton, R. P.; Schindler, J. F.; Hirsch, J. L.; Benson, A. G.; Kurumbail, R. G.; Stegeman, R. A.; Williams, J. M.; Broadus, R. M.; Walden, Z.; Monahan, J. B. Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804 Biochemistry 2009, 48, 6402-6411
24. Duffy, J. P.; Harrington, E. M.; Salituro, F. G.; Cochran, J. E.; Green, J.; Gao, H.; Bemis, G. W.; Evindar, G.; Galullo, V. P.; Ford, P. J.; Germann, U. A.; Wilson, K. P.; Bellon, S. F.; Chen, G.; Taslimi, P.; Jones, P.; Huang, C.; Pazhanisamy, S.; Wang, Y.-M.; Murcko, M. A.; Su, Michael, S. S. The discovery of VX-745: A novel and selective p38α kinase inhibitor ACS Med. Chem. Lett. 2011, 2, 758-763
25. Chu, M. L. H.; Lang, Z.; Chavas, L. M. G.; Neres, J.; Fedorova, O. S.; Tabernero, L.; Cherry, M.; Williams, D. H.; Douglas, K. T.; Eyers, P. A. Biophysical and X-ray crystallographic analysis of Mps1 kinase inhibitor complexes Biochemistry 2010, 49, 1689-1701